Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014777 · ClinicalTrials.gov registry record · Phase 1
Study of NGM621 in Participants With Geographic Atrophy
A Phase 1 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04014777 is a Phase 1 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04014777, a Phase 1 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Interventions
- BIOLOGICAL NGM621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014777
The ClinicalTrials.gov registry entry for NCT04014777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NGM621 is the first listed.
NCT04014777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04014777 about?
NCT04014777 is a clinical study titled "Study of NGM621 in Participants With Geographic Atrophy". This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
What is the current status of trial NCT04014777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-07-26. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT04014777?
The interventions under investigation include: NGM621 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04014777?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.